Cinctive Capital Management LP Sells 51,362 Shares of Annexon, Inc. (NASDAQ:ANNX)

Cinctive Capital Management LP reduced its position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 27.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 135,466 shares of the company’s stock after selling 51,362 shares during the quarter. Cinctive Capital Management LP’s holdings in Annexon were worth $695,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ANNX. Geode Capital Management LLC increased its position in shares of Annexon by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock valued at $11,142,000 after acquiring an additional 27,843 shares in the last quarter. Wellington Management Group LLP boosted its stake in Annexon by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company’s stock valued at $1,376,000 after purchasing an additional 4,806 shares during the last quarter. Prudential Financial Inc. increased its holdings in shares of Annexon by 6.4% in the 4th quarter. Prudential Financial Inc. now owns 171,680 shares of the company’s stock worth $881,000 after purchasing an additional 10,400 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after purchasing an additional 576,625 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Annexon during the fourth quarter valued at $98,000.

Annexon Price Performance

Shares of ANNX opened at $1.83 on Friday. The firm has a market capitalization of $200.77 million, a P/E ratio of -1.74 and a beta of 1.24. Annexon, Inc. has a one year low of $1.73 and a one year high of $7.85. The business has a fifty day moving average of $2.86 and a 200 day moving average of $4.86.

Annexon (NASDAQ:ANNX – Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Analysts expect that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ANNX. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th.

Read Our Latest Analysis on ANNX

Annexon Company Profile

(Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

See Also

• Five stocks we like better than Annexon
• Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
• Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
• Why Are Stock Sectors Important to Successful Investing?
• Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
• Dividend Payout Ratio Calculator
• Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report).